Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — Technical Presentation (November 2019)

8 slides from Aerie Pharmaceuticals's technical presentation, Nov 6, 2019

  1. Slide 1: AR-13324-CS208 Japan Phase 2 Study Topline Results

    AR-13324-CS208 Japan Phase 2 Study Topline Results November 6, 2019 Exhibit 99.1

  2. Slide 2: Important Information

    Important Information The information in this presentation is current only as of its date and may have changed or may change in the future. We are not making any representation or warranty that the information in this presentation is accurate or complete. Certain statements in this presentation are

  3. Slide 3: Japan Phase 2 Executive Summary

    Japan Phase 2 Executive Summary 28-day prospective, double-masked, placebo-controlled, dose-ranging study of netarsudil efficacy and safety in Japanese subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) Netarsudil 0.01%, 0.02% and 0.04% were efficacious and met primary endpoint of

  4. Slide 4: Study Design and Primary Endpoints

    Primary Endpoints Efficacy: Mean diurnal IOP at Week 4 Safety: Ocular/Systemic safety during a 4-week treatment period Japanese patients with Open Angle Glaucoma (OAG) with IOP (unmedicated) ≥ 15 mmHg and < 35 mmHg or Ocular Hypertension (OHT) with IOP (unmedicated) ≥ 22 mmHg and < 35 mmHg N = 215 s

  5. Slide 5: Efficacy – Mean IOP at Each Time Point

    Efficacy – Mean IOP at Each Time Point For Investor Use

  6. Slide 6: Primary Endpoint – Mean Diurnal IOP

    Primary Endpoint – Mean Diurnal IOP P<0.0001 vs. placebo at Week 4 for all dose levels1 0.02% achieved lowest mean diurnal IOP at Week 4 1. ANCOVA with MCMC imputation For Investor Use

  7. Slide 7: Treatment-Emergent Adverse Events and Safety Summary

    Any TEAEs ≥ 2% System Organ Class Preferred Term Netarsudil 0.01% QD (N=55) n (%) Netarsudil 0.02% QD (N=54) n (%) Netarsudil 0.04% QD (N=51) n (%) Placebo (N=55) n (%) Eye Disorders 16 ( 29.1) 22 ( 40.7) 32 ( 62.7) 3 ( 5.5) Conjunctival hyperemia 13 ( 23.6) 20 ( 37.0) 29 ( 56.9) 1 ( 1.8) Eye irrita

  8. Slide 8: Executive Summary

    Japan Phase 2 Executive Summary Netarsudil 0.01%, 0.02% and 0.04% were efficacious and met primary endpoint of superiority to placebo in mean diurnal IOP1 Baseline mean diurnal IOPs were 20 - 21 mmHg across study arms2 Week 4 mean diurnal IOP was 16.3 (-4.1), 15.4 (-4.8), 16.2 (-4.8) and 19.3 (-1.7)

Aerie Pharmaceuticals — Technical Presentation (November 2019) on 6ix